Cargando…
Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation
PURPOSE: To investigate the significance of demographic and pathological characteristics on the survival outcomes of urachal adenocarcinoma (UrAC), primary bladder adenocarcinoma (BAC) and urothelial carcinoma with glandular differentiation (UCGD) in China. MATERIALS AND METHODS: We retrospectively...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133414/ https://www.ncbi.nlm.nih.gov/pubmed/35646691 http://dx.doi.org/10.3389/fonc.2022.860133 |
_version_ | 1784713561405128704 |
---|---|
author | Wang, Tao Lv, Zheng Feng, Huayi Li, Jinlong Cui, Bo Yang, Yang Huang, Xing Zhang, Xiangyi Li, Xintao Ma, Xin |
author_facet | Wang, Tao Lv, Zheng Feng, Huayi Li, Jinlong Cui, Bo Yang, Yang Huang, Xing Zhang, Xiangyi Li, Xintao Ma, Xin |
author_sort | Wang, Tao |
collection | PubMed |
description | PURPOSE: To investigate the significance of demographic and pathological characteristics on the survival outcomes of urachal adenocarcinoma (UrAC), primary bladder adenocarcinoma (BAC) and urothelial carcinoma with glandular differentiation (UCGD) in China. MATERIALS AND METHODS: We retrospectively analyzed cases with non-distant metastases (≤ T4M0). Of 106 patients, 30 (28.3%), 40 (37.7%), and 36 (34.0%) met the criteria for UrAC, primary BAC, and UCGD, respectively. Data on patient demographics, tumor pathology, and survival outcomes were collected. The median follow-up was 36 months. Survival was analyzed using multivariate Cox regression. RESULTS: Patients with UrAC were younger (51.87 ± 15.25 years) than those with primary BAC (60.50 ± 12.56 years) and UCGD (63.83 ± 11.60 years) (P<0.001). Patients with UrAC were the most likely to be stage T3–4 (70.0% vs. 40.0% vs. 44.4%; P<0.001), while the primary BAC group had a higher rate of poor differentiation than the UrAC and UCGD groups (57.4% vs. 18.5% vs. 24.1%; P<0.001). The Kaplan–Meier curves showed that the overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) of the primary BAC group were poorer than those of both the UrAC and UCGD groups (P=0.0046,P<0.0001,P=0.0077 respectively). Regarding BAC, patients with mucinous adenocarcinoma tended to have better OS and PFS than those with other histological types (P<0.005,P=0.0245). Multivariate Cox regression analysis revealed that tumor type (P=0.002), T stage (P=0.034), and the age-adjusted Charlson Comorbidity Index (aCCI) scores (P=0.005) predicted the postoperative OS and DSS of the patients. For PFS, the tumor type (P=0.011), grade (P=0.000), and aCCI (P=0.002) scores were predictive. CONCLUSION: Among UrAC, primary BAC, and UCGD patients, the prognosis was poorest for those with primary BAC. Attempts should be made to diagnose these aggressive tumors early, since patients in whom tumors are detected early appear to survive longer. |
format | Online Article Text |
id | pubmed-9133414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91334142022-05-27 Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation Wang, Tao Lv, Zheng Feng, Huayi Li, Jinlong Cui, Bo Yang, Yang Huang, Xing Zhang, Xiangyi Li, Xintao Ma, Xin Front Oncol Oncology PURPOSE: To investigate the significance of demographic and pathological characteristics on the survival outcomes of urachal adenocarcinoma (UrAC), primary bladder adenocarcinoma (BAC) and urothelial carcinoma with glandular differentiation (UCGD) in China. MATERIALS AND METHODS: We retrospectively analyzed cases with non-distant metastases (≤ T4M0). Of 106 patients, 30 (28.3%), 40 (37.7%), and 36 (34.0%) met the criteria for UrAC, primary BAC, and UCGD, respectively. Data on patient demographics, tumor pathology, and survival outcomes were collected. The median follow-up was 36 months. Survival was analyzed using multivariate Cox regression. RESULTS: Patients with UrAC were younger (51.87 ± 15.25 years) than those with primary BAC (60.50 ± 12.56 years) and UCGD (63.83 ± 11.60 years) (P<0.001). Patients with UrAC were the most likely to be stage T3–4 (70.0% vs. 40.0% vs. 44.4%; P<0.001), while the primary BAC group had a higher rate of poor differentiation than the UrAC and UCGD groups (57.4% vs. 18.5% vs. 24.1%; P<0.001). The Kaplan–Meier curves showed that the overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) of the primary BAC group were poorer than those of both the UrAC and UCGD groups (P=0.0046,P<0.0001,P=0.0077 respectively). Regarding BAC, patients with mucinous adenocarcinoma tended to have better OS and PFS than those with other histological types (P<0.005,P=0.0245). Multivariate Cox regression analysis revealed that tumor type (P=0.002), T stage (P=0.034), and the age-adjusted Charlson Comorbidity Index (aCCI) scores (P=0.005) predicted the postoperative OS and DSS of the patients. For PFS, the tumor type (P=0.011), grade (P=0.000), and aCCI (P=0.002) scores were predictive. CONCLUSION: Among UrAC, primary BAC, and UCGD patients, the prognosis was poorest for those with primary BAC. Attempts should be made to diagnose these aggressive tumors early, since patients in whom tumors are detected early appear to survive longer. Frontiers Media S.A. 2022-05-12 /pmc/articles/PMC9133414/ /pubmed/35646691 http://dx.doi.org/10.3389/fonc.2022.860133 Text en Copyright © 2022 Wang, Lv, Feng, Li, Cui, Yang, Huang, Zhang, Li and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Tao Lv, Zheng Feng, Huayi Li, Jinlong Cui, Bo Yang, Yang Huang, Xing Zhang, Xiangyi Li, Xintao Ma, Xin Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation |
title | Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation |
title_full | Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation |
title_fullStr | Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation |
title_full_unstemmed | Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation |
title_short | Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation |
title_sort | survival of patients with urac and primary bac and urothelial carcinoma with glandular differentiation |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133414/ https://www.ncbi.nlm.nih.gov/pubmed/35646691 http://dx.doi.org/10.3389/fonc.2022.860133 |
work_keys_str_mv | AT wangtao survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation AT lvzheng survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation AT fenghuayi survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation AT lijinlong survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation AT cuibo survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation AT yangyang survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation AT huangxing survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation AT zhangxiangyi survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation AT lixintao survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation AT maxin survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation |